DeepMed Research

SPECTRUM PHARMACEUTICALS, INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1987-01-01

Employees: 101

Market Cap: -

Website: http://www.sppirx.com

Clinical Trials

Phase II Trial of EOquin in High-risk Superficial Bladder Cancer

Phase 2

Completed

Conditions: Bladder Neoplasms

Interventions: Drug: Apaziquone

First Posted Date: 2005-09-01

Last Posted Date: 2012-06-14

Lead Sponsor: Spectrum Pharmaceuticals, Inc

Target Recruit Count: 53

Registration Number: NCT00141531

Locations: 🇳🇱
St Radboud University Hospital, Nijmegen, Netherlands

A Study to Evaluate PT-523 in Patients With Refractory Leukemia

Phase 1

Withdrawn

Conditions: Leukemia

First Posted Date: 2005-08-12

Last Posted Date: 2013-12-04

Lead Sponsor: Spectrum Pharmaceuticals, Inc

Registration Number: NCT00129558

Locations: 🇺🇸
USC, Kennth Norris Jr. Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸
UCLA School of Medicine, Los Angeles, California, United States
🇺🇸
University of Chicago, Chicago, Illinois, United States

and more 3 locations

A Study to Assess the Safety and Preliminary Efficacy of PT-523 in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Phase 1

Withdrawn

Conditions: Non-Small-Cell Lung Carcinoma

First Posted Date: 2005-05-30

Last Posted Date: 2014-03-31

Lead Sponsor: Spectrum Pharmaceuticals, Inc

Registration Number: NCT00112060

Locations: 🇷🇺
Irkutsk Regional Oncology Center, Irkutsk, Russian Federation
🇷🇺
Petrov Research Institute of Oncology, St. Petersburg, Russian Federation
🇺🇸
University of Miami and Sylvester Comprehensive Cancer Center, Miami, Florida, United States

and more 10 locations

Elsamitrucin (SPI 28090) for Relapsed or Refractory Non-Hodgkin's Lymphoma

Phase 2

Completed

Conditions: Mantle Cell Lymphoma
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

First Posted Date: 2004-08-25

Last Posted Date: 2008-01-15

Lead Sponsor: Spectrum Pharmaceuticals, Inc

Target Recruit Count: 114

Registration Number: NCT00090090

Locations: 🇺🇸
Alta Bates Cancer Center, Berkeley, California, United States
🇺🇸
Cancer and Blood Institute Medical Group, Rancho Mirage, California, United States
🇺🇸
Tower Hematology Oncology Medical Group, Los Angeles, California, United States

and more 4 locations

Safety Study of PT-523 in Cancer Patients to Treat Solid Tumors Including a Preliminary Assessment of Effectiveness

Phase 1

Terminated

Conditions: Neoplasms

First Posted Date: 2004-07-20

Last Posted Date: 2014-03-31

Lead Sponsor: Spectrum Pharmaceuticals, Inc

Target Recruit Count: 40

Registration Number: NCT00088023

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Beth Isreal Deaconess Medical Center, Boston, Massachusetts, United States

Combination Chemotherapy, Radiation Therapy, and RSR13 in Treating Patients With Stage III Non-small Cell Lung Cancer

Phase 2

Completed

Conditions: Lung Cancer

First Posted Date: 2004-06-25

Last Posted Date: 2021-08-26

Lead Sponsor: Spectrum Pharmaceuticals, Inc

Registration Number: NCT00004202

Locations: 🇺🇸
Cedars-Sinai Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸
Johns Hopkins Oncology Center, Baltimore, Maryland, United States
🇺🇸
Cancer Center of Albany Medical Center, Albany, New York, United States

and more 13 locations

Whole Brain Radiation Therapy With Oxygen, With or Without RSR13, in Women With Brain Metastases From Breast Cancer

Phase 3

Completed

Conditions: Breast Cancer
Metastases

Interventions: Drug: Efaproxiral
Radiation: Whole Brain Radiation Therapy (WBRT)
Other: Supplemental Oxygen

First Posted Date: 2004-05-19

Last Posted Date: 2013-05-10

Lead Sponsor: Spectrum Pharmaceuticals, Inc

Target Recruit Count: 368

Registration Number: NCT00083304

Locations: 🇺🇸
Maryland Hematology Oncology, Baltimore, Maryland, United States
🇺🇸
Franklin Square Hospital Center, Baltimore, Maryland, United States
🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

and more 89 locations

Radiation Therapy With or Without RSR13 in Treating Patients With Brain Metastases

Phase 3

Completed

Conditions: Metastatic Cancer

First Posted Date: 2003-08-29

Last Posted Date: 2021-08-23

Lead Sponsor: Spectrum Pharmaceuticals, Inc

Registration Number: NCT00005887

Locations: 🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
🇺🇸
State University of New York - Upstate Medical University, Syracuse, New York, United States
🇺🇸
Bismarck Cancer Center, Bismarck, North Dakota, United States

and more 70 locations

Chemotherapy and Radiation Therapy With or Without Efaproxiral in Treating Patients With Stage III Non-Small Cell Lung Cancer

Phase 3

Withdrawn

Conditions: Lung Cancer

First Posted Date: 2003-03-07

Last Posted Date: 2013-05-10

Lead Sponsor: Spectrum Pharmaceuticals, Inc

Registration Number: NCT00055887

Locations: 🇨🇦
CHUS-Hopital Fleurimont, Fleurimont, Quebec, Canada
🇺🇸
Schiffler Cancer Center, Wheeling, West Virginia, United States
🇨🇦
Centre Hospitalier Universitaire de Quebec, Quebec City, Quebec, Canada

and more 19 locations

10-Propargyl-10-Deazaaminopterin in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or Hodgkin's Lymphoma

Phase 1

Completed

Conditions: Lymphoma

Interventions: Drug: pralatrexate

First Posted Date: 2003-01-27

Last Posted Date: 2021-08-25

Lead Sponsor: Spectrum Pharmaceuticals, Inc

Target Recruit Count: 72

Registration Number: NCT00052442

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy